Condition: Medulloblastoma · Medulloblastoma, Non-WNT/Non-SHH · Sponsor: H. Lee Moffitt Cancer Center and Research Institute
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
This description comes directly from the study's public registry record.
Jessica Crimella · 813-745-6250 · Jessica.Crimella@moffitt.org
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Children's of Alabama | Birmingham, Alabama, United States | Recruiting |
| Arkansas Childrens Hospital | Little Rock, Arkansas, United States | Recruiting |
| Connecticut Children's Medical Center | Hartford, Connecticut, United States | Not Yet Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Nemours Jacksonville | Jacksonville, Florida, United States | Not Yet Recruiting |
| University of Miami | Miami, Florida, United States | Not Yet Recruiting |
| Johns Hopkins All Children's | St. Petersburg, Florida, United States | Recruiting |
| St. Joseph's Children's Hospital | Tampa, Florida, United States | Recruiting |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| Washington University St. Louis | St Louis, Missouri, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill, North Carolina, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06701812